Actively Recruiting
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
Led by Jonsson Comprehensive Cancer Center · Updated on 2026-02-05
186
Participants Needed
1
Research Sites
369 weeks
Total Duration
On this page
Sponsors
J
Jonsson Comprehensive Cancer Center
Lead Sponsor
V
Viewray Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial studies the side effects of image-guidance and online adaptation with stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate adenocarcinoma that has not spread to other parts of the body (localized). Image-guided SBRT is a standard treatment for localized prostate cancer. This treatment uses imaging of the cancer within the body to define and localize the area to be treated with the radiation. Imaging can be obtained using either computed tomography (CT), magnetic resonance imaging (MRI), or a combination of the two. Typically, with SBRT, a radiation plan is developed based on the CT or MRI images obtained before treatment begins and adjustments are not made to the plan during treatment. However, anatomy can be different from day-to-day which may cause radiation to be delivered to the normal surrounding structures and possibly more side effects. During image-guided SBRT with online adaptation, the initial radiation plan is designed similarly; however, when the patient presents for radiation, the attending radiation oncologist, a dosimetrist, and a medical physicist "re-optimize" the radiation plan using the current anatomy of the day, meaning the changes in bladder and prostate size/shape are taken into account. The initial plan and the re-optimized plan are then compared, and the plan that has the optimal balance between delivering a tumor killing dose of radiation and minimizing radiation dose to normal surrounding structures is delivered. Image-guidance and online adaptation with SBRT may lower side effects and be a safer way to treat localized prostate adenocarcinoma.
CONDITIONS
Official Title
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically confirmed, clinically localized adenocarcinoma of the prostate
- Completed staging workup based on National Comprehensive Cancer Network (NCCN) risk grouping, including advanced imaging if applicable
- No evidence of metastatic disease above the renal artery bifurcation; nodal disease below this level may be included
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- No urgent need for radiation treatment
- Able to provide written informed consent and comply with study requirements
You will not qualify if you...
- Diagnosis of neuroendocrine or small cell carcinoma of the prostate
- Evidence of distant metastases except for lymphadenopathy below the renal arteries
- Prior whole prostate treatments such as cryosurgery, high-intensity focused ultrasound (HIFU), brachytherapy, or other ablative therapies
- Previous pelvic radiotherapy
- History of Crohn's disease, ulcerative colitis, or ataxia telangiectasia
- Any condition or abnormality deemed by the investigator to compromise participant safety or data quality
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095
Actively Recruiting
Research Team
C
Carol W. Felix
CONTACT
C
Christy Palodichuck
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here